Abstract
The consequences of inhibiting the metabolism of prostaglandin G2 to thromboxane A2 in man were studied by using an inhibitor of thromboxane synthase, 4-[2-(IH-imidazol-1-yl)ethoxy] benzoic acid hydrochloride (dazoxiben). Single doses of 25, 50, 100, and 200 mg of dazoxiben were administered to healthy volunteers at 2-wk intervals in a randomized, placebo-controlled, double-blind manner. Serum thromboxane B2 and aggregation studies in whole blood and platelet-rich plasma were measured before dosing and at 1, 4, 6, 8, and 24 h after dosing. Both serum thromboxane B2 and the platelet aggregation response to arachidonic acid (1.33 mM) were reversibly inhibited in a dose-dependent manner. Aggregation induced by 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (0.4 and 4.0 microM) in platelet-rich plasma as well as both aggregation and nucleotide release induced by collagen (95 micrograms/ml) in platelet-rich plasma and whole blood were unaltered by dazoxiben. Additional evidence for a platelet-inhibitory effect of the compound was a significant prolongation of the bleeding time at 1 h after administration of the highest dose (200 mg) of dazoxiben. Endogenous prostacyclin biosynthesis was assessed by measurement of the major urinary metabolite of prostacyclin, 2,3-dinor-6-keto-PGF1 alpha (PGI-M). PGI-M excretion was increased by dazoxiben; it rose a mean 2.4-fold from predosing control values at 0-6 h after administration of the highest dose studied (200 mg).
Full text
PDF







Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
- Bartele V., Cerletti C., Schiepatti A., di Minno G., de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet. 1981 May 9;1(8228):1057–1058. doi: 10.1016/s0140-6736(81)92224-8. [DOI] [PubMed] [Google Scholar]
- Blair I. A., Barrow S. E., Waddell K. A., Lewis P. J., Dollery C. T. Prostacyclin is not a circulating hormone in man. Prostaglandins. 1982 Apr;23(4):579–589. doi: 10.1016/0090-6980(82)90118-6. [DOI] [PubMed] [Google Scholar]
- Bunting S., Gryglewski R., Moncada S., Vane J. R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976 Dec;12(6):897–913. doi: 10.1016/0090-6980(76)90125-8. [DOI] [PubMed] [Google Scholar]
- Butler K. D., Maguire E. D., Smith J. R., Turnbull A. A., Wallis R. B., White A. M. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation. Thromb Haemost. 1982 Feb 26;47(1):46–49. [PubMed] [Google Scholar]
- Cardinal D. C., Flower R. J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135–158. doi: 10.1016/0160-5402(80)90024-8. [DOI] [PubMed] [Google Scholar]
- Dawson W., Boot J. R., Cockerill A. F., Mallen D. N., Osborne D. J. Release of novel prostaglandins and thromboxanes after immunological challenge of guinea pig lung. Nature. 1976 Aug 19;262(5570):699–702. doi: 10.1038/262699a0. [DOI] [PubMed] [Google Scholar]
- Falardeau P., Oates J. A., Brash A. R. Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Anal Biochem. 1981 Aug;115(2):359–367. doi: 10.1016/0003-2697(81)90018-x. [DOI] [PubMed] [Google Scholar]
- Feinman R. D., Lubowsky J., Charo I., Zabinski M. P. The lumi-aggregometer: a new instrument for simultaneous measurement of secretion and aggregation by platelets. J Lab Clin Med. 1977 Jul;90(1):125–129. [PubMed] [Google Scholar]
- FitzGerald G. A., Brash A. R., Falardeau P., Oates J. A. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FitzGerald G. A., Friedman L. A., Miyamori I., O'Grady J., Lewis P. J. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 1979 Aug 20;25(8):665–672. doi: 10.1016/0024-3205(79)90507-1. [DOI] [PubMed] [Google Scholar]
- FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FitzGerald G. A., Sherry S. Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res. 1982;10:107–172. [PubMed] [Google Scholar]
- Fitzpatrick F. A., Gorman R. R. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors. Biochim Biophys Acta. 1978 Mar 1;539(2):162–172. doi: 10.1016/0304-4165(78)90003-x. [DOI] [PubMed] [Google Scholar]
- Fitzpatrick F. A., Gorman R. R., Mc Guire J. C., Kelly R. C., Wynalda M. A., Sun F. F. A radioimmunoassay for thromboxane B2. Anal Biochem. 1977 Sep;82(1):1–7. doi: 10.1016/0003-2697(77)90127-0. [DOI] [PubMed] [Google Scholar]
- Gorman R. R. Biology and biochemistry of thromboxane synthetase inhibitors. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:235–240. [PubMed] [Google Scholar]
- Grimm L. J., Knapp D. R., Senator D., Halushka P. V. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res. 1981 Nov 15;24(4):307–317. doi: 10.1016/0049-3848(81)90004-9. [DOI] [PubMed] [Google Scholar]
- Heptinstall S., Bevan J., Cockbill S. R., Hanley S. P., Parry M. J. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219–230. doi: 10.1016/0049-3848(80)90387-4. [DOI] [PubMed] [Google Scholar]
- Ingerman-Wojenski C. M., Smith J. B., Silver M. J. Difficulty in detecting inhibition of platelet aggregation by the impedance method. Thromb Res. 1982 Nov 1;28(3):427–432. doi: 10.1016/0049-3848(82)90124-4. [DOI] [PubMed] [Google Scholar]
- Ito T., Ogawa K., Sakai K., Watanabe J., Satake T., Kayama N., Hiraku S., Naito J. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:245–251. [PubMed] [Google Scholar]
- Marcus A. J. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res. 1978 Sep;19(7):793–826. [PubMed] [Google Scholar]
- Marcus A. J., Weksler B. B., Jaffe E. A., Broekman M. J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest. 1980 Nov;66(5):979–986. doi: 10.1172/JCI109967. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Needleman P. Prostacyclin in blood vessel-platelet interactions: perspectives and questions. Nature. 1979 May 3;279(5708):14–15. doi: 10.1038/279014a0. [DOI] [PubMed] [Google Scholar]
- Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parry M. J., Randall M. J., Tyler H. M., Myhre E., Dale J., Thaulow E. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers. Lancet. 1982 Jul 17;2(8290):164–164. doi: 10.1016/s0140-6736(82)91137-0. [DOI] [PubMed] [Google Scholar]
- Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372. doi: 10.1172/JCI110576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pedersen A. K., Jakobsen P. Sulphinpyrazone metabolism during long-term therapy. Br J Clin Pharmacol. 1981 Jun;11(6):597–603. doi: 10.1111/j.1365-2125.1981.tb01176.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pedersen A. K., Jakobsen P. Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect. Thromb Res. 1979;16(5-6):871–876. doi: 10.1016/0049-3848(79)90233-0. [DOI] [PubMed] [Google Scholar]
- Preston F. E., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med. 1981 Jan 8;304(2):76–79. doi: 10.1056/NEJM198101083040203. [DOI] [PubMed] [Google Scholar]
- Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tyler H. M., Saxton C. A., Parry M. J. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet. 1981 Mar 21;1(8221):629–632. doi: 10.1016/s0140-6736(81)91551-8. [DOI] [PubMed] [Google Scholar]
- Vermylen J., Defreyn G., Carreras L. O., Machin S. J., Van Schaeren J., Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet. 1981 May 16;1(8229):1073–1075. doi: 10.1016/s0140-6736(81)92241-8. [DOI] [PubMed] [Google Scholar]